WO2005011687A1 - Transdermales therapeutisches system mit dem wirkstoff pramipexol - Google Patents
Transdermales therapeutisches system mit dem wirkstoff pramipexol Download PDFInfo
- Publication number
- WO2005011687A1 WO2005011687A1 PCT/EP2004/007770 EP2004007770W WO2005011687A1 WO 2005011687 A1 WO2005011687 A1 WO 2005011687A1 EP 2004007770 W EP2004007770 W EP 2004007770W WO 2005011687 A1 WO2005011687 A1 WO 2005011687A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- pramipexole
- tts
- tts according
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a transdermal therapeutic system (TTS) for the administration of pramipexole.
- TTS transdermal therapeutic system
- a self-adhesive Pramipexol-TTS which is capable of continuously delivering the active ingredient Pramipexol as a base over a longer period of time, preferably 4 to 7 days, to a person who is dependent on a continuous supply with an effective amount of this active ingredient.
- a transdermal therapeutic system is a layered pharmaceutical dosage form which consists of at least one polymer layer containing an active ingredient and a backing layer which is generally impermeable to the active ingredient.
- the TTS can also contain other layers, often e.g. B. a membrane controlling the rate of release of the active ingredient, ensuring the adhesion of the TTS to the patient's skin
- a TTS is capable of delivering the active ingredient continuously and in a controlled manner to the patient's skin. After passing through the various outer layers of the skin, the active pharmaceutical ingredient is absorbed by the underlying blood vessels. Due to the continuous release, particularly uniform plasma levels are obtained. Transdermal administration also has the advantage of bypassing the gastrointestinal tract.
- the active ingredient pramipexole has the chemical name (S) -2-amino-4,5,6,7-tetrahydro-6- (propylamino) benzothiazole. Chemically speaking, the active substance is a base. He has the CAS registry number. [104632-26-0] and is considered the first non-ergotic, presynaptic dopamine D2 agonist.
- the active ingredient is available in the form of the hydrochloride as a tablet under the brand names Sifrol ® and Mirapex ® . As such, it is used as a Parkinson's drug and to treat extrapyramidal disorders. Pramipexole is used in idiopathic (without identifiable cause, as it were self-developed) Parkinson's disease both in the early stage and in the advanced stage, here also in combination with levodopa.
- the individual dose that is optimally matched to the effectiveness and tolerability must first be determined for each patient.
- This dose titration is usually carried out at weekly intervals, with an amount of pramipexole hydrochloride corresponding to 0.088 mg of pramipexole base being administered three times a day for the first week.
- an amount of pramipexole hydrochloride equivalent to 0.18 mg of pramipexole base is administered three times a day.
- an amount of pramipexole hydrochloride equivalent to 0.36 mg of pramipexole base is administered three times a day.
- the average daily dose generally corresponds to 1.5 mg of pramipexole hydrochloride, which means that 0.36 mg of pramipexole base is administered orally three times a day.
- Parkinson's disease is a disease of the trunk ganglia that is mainly characterized by movement disorders.
- pramipexole is also used to treat the so-called restless-Ieg syndrome; compare DE 197 01 619 A1, to which reference is made in full.
- transdermal therapeutic systems with the active ingredient pramipexol, in particular its (-) enantiomer, and pharmaceutically acceptable acid addition salts.
- TTS transdermal therapeutic systems
- EP 428 038 A2 describes transdermal therapeutic systems with an active substance reservoir made from an emulsion-polymerized polyacrylate and 5 to 30% by weight of the active substance pramipexole.
- Eudragit NE 30 D ® from Röhm GmbH Darmstadt is used as the preferred carrier material.
- This product is available in the form of an aqueous dispersion of a copolymer with a neutral character based on ethyl acrylate and methyl methacrylate with a dry matter content of 30%. The average molecular weight is 800,000.
- Films containing active ingredient can be produced from Eudragit NE 30 D ® , but these are not pressure-sensitive adhesives.
- the active substance-containing reservoirs in special embodiments of these TTS have an area of 20 cm 2 , a thickness of 200 ⁇ m and an active substance content of 9% by weight.
- the active substance-containing reservoirs provided with a covering plaster for attachment to the skin were able to deliver a daily dose of about 2.5 mg to two test subjects over a period of 3 or 4 days.
- US Pat. No. 6,465,004 B1 discloses a transdermal therapeutic system which, in addition to the active pharmaceutical ingredient and one or more adhesives, contains cellulose acetate butyrate as a water-insoluble but soluble component. This is an esterified cellulose derivative, which is intended to prevent the crystallization of the active ingredient in the pressure sensitive adhesive.
- Pramipexole is also considered as an active pharmaceutical ingredient. However, it is not disclosed whether a suitably structured pramipexole TTS is suitable for the continuous administration of the active ingredient over a longer period of time, preferably 4 to 7 days.
- German patent application DE 10033 853 A1 discloses transdermal therapeutic systems which, in addition to the active pharmaceutical ingredient (including pramipexole) and a matrix material, contain highly disperse silicon dioxide as a further constituent.
- a pramipexole TTS which is capable of continuously administering an effective amount of this active ingredient over a longer period of time, preferably 4 to 7 days, is not disclosed.
- the object of the present invention is to provide a self-adhesive transdermal therapeutic system (TTS) which - after determining an individual daily dose - continuously releases the active ingredient pramipexole to the patient in the long-term phase of the therapy without the need for oral administration three times a day Tablet is necessary.
- TTS self-adhesive transdermal therapeutic system
- the active ingredient-containing polymer layer or the side of the TTS facing the skin should also be provided with a pressure-sensitive adhesive, so that the use of an additional pressure-sensitive adhesive plaster for fixing on the skin can be dispensed with.
- the administration of a transdermal therapeutic system should preferably take place in a manner which provides the patient with sufficient active substance for a longer period, preferably for 4 to 7 days.
- TTS transdermal therapeutic system
- Such a TTS contains a - preferably active substance-impermeable - backing layer, at least one active substance-containing layer and a protective layer to be removed before use, the active substance-containing layer containing the active substance pramipexole.
- the S - (-) enantiomer, as well as the? - (+) - enantiomer and a - preferably racemic - mixture of these two enantiomers, preferably the S - (-) enantiomer are referred to as pramipexole understand.
- pramipexole can be used as the free base, as a hydrate, solvate or pharmaceutically acceptable salt (e.g. as a hydrochloride) in the at least one Active ingredient-containing layer may be included.
- the use of pramipexole as the S - (-) enantiomer in the form of the free base is particularly preferred.
- the active substance-containing layer also contains a pressure sensitive adhesive which is capable of securely attaching the TTS to a single point on the skin of the user during the entire application period, preferably from 4 to 7 days.
- the TTS can also contain further layers, for example a membrane controlling the rate of release of the active ingredient, at least one additional active ingredient-containing layer, at least one support layer to increase the mechanical stability of the TTS and a pressure-sensitive adhesive layer on the side of the TTS facing the skin.
- Pressure sensitive adhesives that are suitable for the layer containing the active substance and, if applicable, the pressure sensitive adhesive layer located on the side of the TTS facing the skin come from the group of silicones, polyisobutylenes and polyacrylates. Polyacrylates (acrylic pressure sensitive adhesives) without carboxyl groups have proven to be particularly suitable.
- Silicone pressure sensitive adhesives e.g. Dow Corning Bio-PSA Q7-4301
- pressure sensitive adhesives based on polyisobutylene / polybutene (PIB / PB) and combinations of styrene-isoprene-styrene block copolymers in combination with adhesive resins were also suitable.
- the active substance-containing layer can consist of a single, preferably homogeneous, active substance-containing pressure-sensitive adhesive layer, but can also be composed of two or more layers which differ in the polymer and active substance composition.
- the pressure sensitive adhesive layer can also be built up from a mixture of two or more different pressure sensitive adhesives.
- Polyacrylates are generally produced by polymerizing various monomers (at least one monomer from the group comprising acrylic acid, methacrylic acid, acrylic acid esters and methacrylic acid esters, if appropriate together with vinyl acetate) and in particular from their mixtures.
- Organic solvents in some cases also water, are preferably used as solvents in the polymerization to produce a suitable polyacrylate.
- polyacrylates are obtained which may contain functional groups.
- Polyacrylates with -OH groups (hydroxyl groups) and those with -COOH groups (carboxyl groups) as functional groups are widespread.
- hydroxyl-containing polyacrylates are obtained as the only monomer or as a constituent in the monomer mixture.
- Polyacrylates containing carboxyl groups are formed when acrylic acid and / or methacrylic acid are used as the monomer or in the monomer mixture.
- Carboxyl group-free polyacrylates are therefore those which are prepared from a monomeric (meth) acrylic acid derivative or a corresponding monomer mixture without using acrylic acid or methacrylic acid.
- the hydroxyl-containing polyacrylates include, for example, Durotak 2287, the monomer composition of which, according to WO 96/40087, is vinyl acetate, 2-ethylhexyl acrylate, hydroxyethyl acrylate and glycidyl acrylate and which is manufactured by National Starch.
- This polyacrylate has proven to be a stable and well-tolerated pressure-sensitive polymer for the production of transdermal therapeutic systems.
- pressure-sensitive adhesives from the group of polyacrylates are capable of absorbing pramipexole in a sufficient amount and of fulfilling the desired controlled release requirements over a longer period of preferably 4 to 7 days, which are free of carboxyl groups. It is not necessary to use additives to create pH-controlled conditions on the skin (e.g. a weak acid, a weak base or inorganic or organic salts that form a buffer system on the skin), crystallization inhibitors or highly disperse silicon dioxide in a penetration-promoting amount to add to the matrix.
- These pressure-sensitive adhesives from the group of polyacrylates are produced exclusively by polymerization in an organic solvent or solvent mixture - not in water or an aqueous dispersion.
- Polymers which can be prepared from monomers from the group comprising acrylic acid esters, methacrylic acid esters and mixtures thereof, optionally with additional vinyl acetate, are thus suitable as polyacrylates.
- acrylic acid esters and methacrylic acid esters are those which carry linear, branched or cyclic aliphatic C Ci2 substituents without other functional groups.
- This group includes in particular n-butyl acrylate, n-butyl methacrylate, ethyl acrylate, 2-ethylhexyl acrylate, ethyl methacrylate, methyl acrylate, methyl methacrylate, tert-butyl acrylate, sec-butyl acrylate, tert-butyl methacrylate, cyclohexyl methacrylate, 2-ethylhexyl methacrylate, 2-ethylhexyl methacrylate, Isopropyl acrylate and isopropyl methacrylate. 2-Ethylhexyl acrylate and methyl acrylate are particularly preferred.
- acrylic acid esters and methacrylic acid esters which contain functional groups can also be contained in the monomer mixture used to prepare the polyacrylate. These are primarily to be understood as meaning esters containing hydroxyl groups, that is to say 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, 3-hydroxypropyl acrylate and 3-hydroxypropyl methacrylate. However, substances such as acrylamide, dimethylaminoethyl acrylate, etc. can also be understood as functional groups-containing acrylic acid esters and methacrylic acid esters.
- the proportion of acrylic acid esters and methacrylic acid esters containing such functional groups should be less than or equal to 10% by weight in the monomer mixture.
- the proportion of acrylic acid esters containing functional groups and methacrylic acid esters containing functional groups in the monomer mixture is preferably less than 2% by weight.
- the proportion of functional groups-containing acrylic acid esters and functional group-containing methacrylic acid esters in the monomer mixture is less than 0.2% by weight.
- a monomer mixture which contains no functional groups-containing acrylic acid esters and methacrylic acid esters is particularly preferred.
- vinyl acetate can also be used as a co-monomer together with at least one monomer from the group of acrylic acid esters and methacrylic acid esters for the preparation of the polyacrylate.
- the proportion of vinyl acetate in the monomer mixture used to prepare this polyacrylate should be below 50% by weight, preferably below 25% by weight.
- a vinyl acetate content between 0 and 5% by weight is particularly preferred.
- the proportion of pramipexole in the form of the base in dissolved, emulsified or dispersed form in one of the above-mentioned pressure sensitive adhesives can be below 75% by weight. It is preferably in the range between 2 and 40% by weight, a range between 10 and 25% by weight is particularly preferred.
- the optimal loading of the pressure sensitive adhesive with active ingredient also depends on the special requirements with regard to the release desired in time, the presence of further constituents in the active ingredient-containing pressure sensitive adhesive layer and the physico-chemical conditions that are present as a result. If the active ingredient pramipexole is dispersed in the active ingredient-containing layer, the solid particles of the active ingredient preferably have a size below 20 ⁇ m.
- the transdermal therapeutic systems can contain one or more solvents for improved solution of the active ingredient in the polymer.
- Propylene glycol, butanediol and lauryl lactate are particularly preferred.
- the TTS may contain antioxidants to increase stability, e.g. As ascorbic acid, esters of ascorbic acid, sodium EDTA, bisulfite, etc., which can preferably be contained in a weight fraction up to 1% in the active ingredient-containing layer. Also, storing the TTS in an airtight manner
- a particularly preferred transdermal therapeutic system is capable of delivering pramipexole over a period of 8 hours after application to 72 hours after application with a flux rate above 5 ⁇ g / cm 2 h.
- Pramipexole can be used by means of the transdermal therapeutic system described here for therapeutic treatment or for reducing the symptoms of depression, tremor, ADHD (attention deficit hyperactivity disorder), anhedonia, HIV dementia, drug addiction and schizophrenia. It is preferred for the treatment of ALS (amyotrophic lateral scierosis), obesity (obesity), obesity and diabetes, as well as for its neuroprotective effect and its anticonvulsant effect.
- the TTS containing pramipexole is particularly preferably used in the restless leg syndrome and in Parkinson's disease.
- Example 1 A mixture is produced from 10% by weight of pramipexole (as base), 20% by weight of butanediol and 70% by weight of Durotak 2287, which is applied by means of a doctor blade to a backing film which serves as a backing layer after drying.
- pressure-sensitive adhesive layer with a basis weight of 200 g / m 2 is spread. TTS patterns which can be used for in vitro investigations are punched out of the two-layer laminate of backing layer and active ingredient-containing PSA layer obtained in this way.
- Example 2 A mixture is produced from 10% by weight of pramipexole (as base), 20% by weight of butanediol and 70% by weight of Durotak 2287, which is applied by means of a doctor blade to a backing film which serves as a backing layer after drying.
- pressure-sensitive adhesive layer with a basis weight of 200 g / m 2 is spread. TTS patterns which can be used for in vitro investigations are punched out of the two-layer laminate of backing layer and active ingredient
- a TTS consisting of a backing layer and two active substance layers is produced.
- the first active substance-containing layer (reservoir layer) consists of 40% by weight of Pramipexol (base) and 60% by weight of Durotak 2287 and has a weight per unit area of 100 g / m 2 .
- the second active substance-containing layer (pressure-sensitive adhesive layer) consists of 3% by weight of Pramipexol (base) and 97% by weight of Durotak 2287 and has a weight per unit area of 30 g / m 2 .
- TTS patterns for the in vitro examinations are punched out of the laminate thus obtained, which consists of a backing layer, reservoir layer and pressure-sensitive adhesive layer.
- Formulations which contain at least one active ingredient-containing layer with 10 to 40% by weight pramipexole in the form of the base are suitable for continuous transdermal administration of this active ingredient for up to 7 days.
- Adhesives which have carboxyl functions as functional groups in the polymer e.g. Durotak 2051 or Durotak 2353
- i.e. H. which were produced using acrylic acid or methacrylic acid.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006520736A JP4925823B2 (ja) | 2003-07-23 | 2004-07-14 | プラミペキソール活性剤を含む経皮治療システム |
US10/564,932 US20060182791A1 (en) | 2003-07-23 | 2004-07-14 | Transdermaltherapeutic system containing a pramipexol active agent |
EP04740987A EP1651215A1 (de) | 2003-07-23 | 2004-07-14 | Transdermales therapeutisches system mit dem wirkstoff pramipexol |
BRPI0412240-2A BRPI0412240A (pt) | 2003-07-23 | 2004-07-14 | sistema terapêutico transdérmico com a substáncia ativa pramipexol |
CA002532904A CA2532904A1 (en) | 2003-07-23 | 2004-07-14 | Transdermal therapeutic system containing a pramipexol active agent |
AU2004260583A AU2004260583B2 (en) | 2003-07-23 | 2004-07-14 | Transdermaltherapeutic system containing a pramipexol active agent |
US13/473,724 US20120225103A1 (en) | 2003-07-23 | 2012-05-17 | Transdermal Therapeutic System Containing a Pramipexol Active Agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10333393.2 | 2003-07-23 | ||
DE10333393A DE10333393A1 (de) | 2003-07-23 | 2003-07-23 | Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/473,724 Continuation US20120225103A1 (en) | 2003-07-23 | 2012-05-17 | Transdermal Therapeutic System Containing a Pramipexol Active Agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005011687A1 true WO2005011687A1 (de) | 2005-02-10 |
Family
ID=34088745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/007770 WO2005011687A1 (de) | 2003-07-23 | 2004-07-14 | Transdermales therapeutisches system mit dem wirkstoff pramipexol |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060182791A1 (de) |
EP (1) | EP1651215A1 (de) |
JP (1) | JP4925823B2 (de) |
KR (1) | KR20060113638A (de) |
CN (1) | CN100450482C (de) |
AU (1) | AU2004260583B2 (de) |
BR (1) | BRPI0412240A (de) |
CA (1) | CA2532904A1 (de) |
DE (1) | DE10333393A1 (de) |
WO (1) | WO2005011687A1 (de) |
ZA (1) | ZA200600206B (de) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007022182A1 (en) * | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestoration with r(+) pramipexole |
WO2008001200A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
JP2009537565A (ja) * | 2006-05-16 | 2009-10-29 | ノップ ニューロサイエンシーズ、インク. | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 |
EP2136638A1 (de) * | 2007-03-14 | 2009-12-30 | Knopp Neurosciences, Inc. | Modifizierte freisetzungsformulierungen von (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazoldiamin und verwendungsverfahren |
WO2010010141A1 (en) * | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pramipexole for treating cardiomyopathy |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
DE102012205493A1 (de) | 2012-04-03 | 2013-10-10 | Acino Ag | Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9642840B2 (en) | 2013-08-13 | 2017-05-09 | Knopp Biosciences, Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9763918B2 (en) | 2013-08-13 | 2017-09-19 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
US9849116B2 (en) | 2008-08-19 | 2017-12-26 | Knopp Biosciences Llc | Compositions and methods of using (R)-pramipexole |
US10383857B2 (en) | 2013-07-12 | 2019-08-20 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US20080254117A1 (en) * | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
JP5652867B2 (ja) * | 2009-11-20 | 2015-01-14 | 日東電工株式会社 | 医療用粘着剤組成物 |
JP5665116B2 (ja) * | 2009-11-20 | 2015-02-04 | 日東電工株式会社 | 貼付剤および貼付製剤 |
US20140045801A1 (en) * | 2012-08-09 | 2014-02-13 | Mylan Inc. | Pramipexole transdermal delivery for severe headaches |
US9682068B2 (en) * | 2013-05-20 | 2017-06-20 | Mylan Inc. | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders |
CN103610666A (zh) * | 2013-12-11 | 2014-03-05 | 中国药科大学 | 一种盐酸普拉克索透皮贴剂及其制备方法 |
US10045948B2 (en) | 2014-02-27 | 2018-08-14 | Medrx Co., Ltd. | Pramipexole-containing transdermal patch for treatment of neurodegenerative disease |
US9837244B2 (en) * | 2014-12-26 | 2017-12-05 | Industrial Technology Research Insitute | Sample holding device for studying light-driven reactions and sample analysis method using the same |
CN104510725B (zh) * | 2015-01-22 | 2021-04-27 | 中国药科大学 | 一种普拉克索周效透皮贴剂及其制备方法 |
CN114796163A (zh) * | 2016-10-07 | 2022-07-29 | 全崴生技股份有限公司 | 普拉克索经皮贴片系统与用法 |
CN109999012A (zh) * | 2019-03-26 | 2019-07-12 | 大道隆达(北京)医药科技发展有限公司 | 一种普拉克索透皮贴剂及其制备方法 |
CN111904950B (zh) * | 2019-05-07 | 2023-05-05 | 上海京新生物医药有限公司 | 一种普拉克索透皮贴剂 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0428038A2 (de) * | 1989-11-09 | 1991-05-22 | Boehringer Ingelheim Kg | Transdermale Applikation von 2-Amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
WO1996018395A1 (en) * | 1994-12-15 | 1996-06-20 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
WO2000074661A2 (en) * | 1999-06-05 | 2000-12-14 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
WO2002003969A2 (de) * | 2000-07-12 | 2002-01-17 | Hexal Ag | Transdermales therapeutisches system mit hochdispersem siliziumdioxid |
WO2003011291A1 (de) * | 2001-07-30 | 2003-02-13 | Hexal Ag | Transdermales therapeutisches system (reservoir-tts) zur anwendung von pramipexol und ropinirol |
WO2003015779A2 (de) * | 2001-07-28 | 2003-02-27 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3315272C2 (de) * | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
AU6032696A (en) * | 1995-06-07 | 1996-12-30 | Cygnus Therapeutic Systems | Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
MXPA02004151A (es) * | 1999-10-28 | 2002-10-17 | 3M Innovative Properties Co | Dispositivos de suministro de medicamento transdermico. |
KR100846642B1 (ko) * | 2001-03-07 | 2008-07-16 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
-
2003
- 2003-07-23 DE DE10333393A patent/DE10333393A1/de not_active Ceased
-
2004
- 2004-07-14 BR BRPI0412240-2A patent/BRPI0412240A/pt not_active IP Right Cessation
- 2004-07-14 EP EP04740987A patent/EP1651215A1/de not_active Withdrawn
- 2004-07-14 CN CNB2004800210396A patent/CN100450482C/zh not_active Expired - Fee Related
- 2004-07-14 AU AU2004260583A patent/AU2004260583B2/en not_active Ceased
- 2004-07-14 CA CA002532904A patent/CA2532904A1/en not_active Abandoned
- 2004-07-14 KR KR1020067001495A patent/KR20060113638A/ko not_active Application Discontinuation
- 2004-07-14 JP JP2006520736A patent/JP4925823B2/ja not_active Expired - Fee Related
- 2004-07-14 US US10/564,932 patent/US20060182791A1/en not_active Abandoned
- 2004-07-14 WO PCT/EP2004/007770 patent/WO2005011687A1/de active Search and Examination
-
2006
- 2006-01-09 ZA ZA200600206A patent/ZA200600206B/en unknown
-
2012
- 2012-05-17 US US13/473,724 patent/US20120225103A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0428038A2 (de) * | 1989-11-09 | 1991-05-22 | Boehringer Ingelheim Kg | Transdermale Applikation von 2-Amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
WO1996018395A1 (en) * | 1994-12-15 | 1996-06-20 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
WO2000074661A2 (en) * | 1999-06-05 | 2000-12-14 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
WO2002003969A2 (de) * | 2000-07-12 | 2002-01-17 | Hexal Ag | Transdermales therapeutisches system mit hochdispersem siliziumdioxid |
WO2003015779A2 (de) * | 2001-07-28 | 2003-02-27 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol |
WO2003011291A1 (de) * | 2001-07-30 | 2003-02-13 | Hexal Ag | Transdermales therapeutisches system (reservoir-tts) zur anwendung von pramipexol und ropinirol |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006279643B2 (en) * | 2005-08-15 | 2010-06-17 | University Of Virginia Patent Foundation | Neurorestoration with R(+) pramipexole |
WO2007022182A1 (en) * | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestoration with r(+) pramipexole |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US8445474B2 (en) | 2006-05-16 | 2013-05-21 | Knopp Neurosciences, Inc. | Compositions of R(+) and S(−) pramipexole and methods of using the same |
JP2009537565A (ja) * | 2006-05-16 | 2009-10-29 | ノップ ニューロサイエンシーズ、インク. | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 |
US8017598B2 (en) | 2006-05-16 | 2011-09-13 | Knopp Neurosciences, Inc. | Compositions of R(+) and S(−) pramipexole and methods of using the same |
WO2008001200A3 (en) * | 2006-06-29 | 2008-06-05 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
WO2008001200A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
EP2136638A1 (de) * | 2007-03-14 | 2009-12-30 | Knopp Neurosciences, Inc. | Modifizierte freisetzungsformulierungen von (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazoldiamin und verwendungsverfahren |
EP2136638A4 (de) * | 2007-03-14 | 2010-05-12 | Knopp Neurosciences Inc | Modifizierte freisetzungsformulierungen von (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazoldiamin und verwendungsverfahren |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
US10179774B2 (en) | 2007-03-14 | 2019-01-15 | Knopp Biosciences Llc | Synthesis of chirally purified substituted benzothiazole diamines |
WO2010010141A1 (en) * | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pramipexole for treating cardiomyopathy |
US9849116B2 (en) | 2008-08-19 | 2017-12-26 | Knopp Biosciences Llc | Compositions and methods of using (R)-pramipexole |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US10208003B2 (en) | 2011-12-22 | 2019-02-19 | Knopp Biosciences Llc | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
DE102012205493A1 (de) | 2012-04-03 | 2013-10-10 | Acino Ag | Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem |
WO2013150032A1 (de) | 2012-04-03 | 2013-10-10 | Acino Ag | Einen dopamin-agonisten enthaltendes transdermales applikationssystem |
US10285981B2 (en) | 2013-02-28 | 2019-05-14 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9956206B2 (en) | 2013-02-28 | 2018-05-01 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US10383856B2 (en) | 2013-07-12 | 2019-08-20 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
US10383857B2 (en) | 2013-07-12 | 2019-08-20 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
US10828284B2 (en) | 2013-07-12 | 2020-11-10 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils |
US10980783B2 (en) | 2013-07-12 | 2021-04-20 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
US11026928B2 (en) | 2013-07-12 | 2021-06-08 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils |
US11612589B2 (en) | 2013-07-12 | 2023-03-28 | Areteia Therapeutics, Inc. | Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils |
US10028940B2 (en) | 2013-08-13 | 2018-07-24 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
US10195183B2 (en) | 2013-08-13 | 2019-02-05 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
US9763918B2 (en) | 2013-08-13 | 2017-09-19 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
US9642840B2 (en) | 2013-08-13 | 2017-05-09 | Knopp Biosciences, Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
US10456381B2 (en) | 2013-08-13 | 2019-10-29 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
Also Published As
Publication number | Publication date |
---|---|
ZA200600206B (en) | 2007-02-28 |
AU2004260583B2 (en) | 2010-01-28 |
CA2532904A1 (en) | 2005-02-10 |
CN100450482C (zh) | 2009-01-14 |
EP1651215A1 (de) | 2006-05-03 |
US20120225103A1 (en) | 2012-09-06 |
JP2006528144A (ja) | 2006-12-14 |
JP4925823B2 (ja) | 2012-05-09 |
DE10333393A1 (de) | 2005-02-24 |
AU2004260583A1 (en) | 2005-02-10 |
CN1826113A (zh) | 2006-08-30 |
US20060182791A1 (en) | 2006-08-17 |
KR20060113638A (ko) | 2006-11-02 |
BRPI0412240A (pt) | 2006-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1651215A1 (de) | Transdermales therapeutisches system mit dem wirkstoff pramipexol | |
EP1033978B1 (de) | D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung | |
DE60304477T2 (de) | Verbessertes transdermales abgabesystem für die verabreichung von rotigotin | |
EP1103260B1 (de) | Transdermalsystem zur Abgabe von Clonidin | |
DE69916492T3 (de) | Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen | |
DE10137082A1 (de) | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol | |
DE112014002664T5 (de) | Transdermales Verabreichungssystem | |
DE10261696A1 (de) | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base | |
EP1492517A2 (de) | Heissschmelz-tts zur verabreichungvon rotigotin | |
EP1347749A2 (de) | Transdermales therapeutisches system mit dem wirkstoff oxybutynin | |
DE60311449T2 (de) | Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen | |
EP1501499A1 (de) | Transepikutane darreichungsform zur behandlung des restless leg syndroms | |
DE102006019293A1 (de) | Pflaster, enthaltend ein Fentanyl Analogum | |
EP1303278A1 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
DE60309329T2 (de) | Verbessertes transdermales abgabesystem | |
DE10315878B4 (de) | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung | |
EP2366388A1 (de) | Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin | |
EP0742716B1 (de) | Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid | |
DE4229230C2 (de) | Transdermales therapeutisches System mit Pentetrazol als Wirkstoff | |
DE60108870T2 (de) | Transdermales Verabreichungssystem für die Behandlung von Harnwegserkrankungen | |
WO2004019892A2 (en) | Drug delivery system for treating urinary incontinence | |
WO2002049606A2 (de) | Transdermalsysteme (tds) enthaltend inhibitoren der phosphodiesterase iv | |
EP3854388B1 (de) | Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber | |
DE102021128912A1 (de) | Okklusives pflaster mit flexibler backing | |
DE202022104940U1 (de) | Transdermales Reservoirpflaster für Vitamin E-Acetat und Efinaconazol in Pflastern zur Verbandarzneimittelabgabe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480021039.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006/00206 Country of ref document: ZA Ref document number: 200600206 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006182791 Country of ref document: US Ref document number: 10564932 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2532904 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/000779 Country of ref document: MX Ref document number: 2006520736 Country of ref document: JP Ref document number: 2004260583 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004740987 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067001495 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004260583 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004740987 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 10564932 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0412240 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067001495 Country of ref document: KR |